Relmada Therapeutics Inc. Common Stock (RLMD)
Stock · NASDAQ · Health Care
$3.1as of 10/16/2026
Price chart
Active signals
RLMD Signal Track Record
How signals performed across all stocks →What RLMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +1.6% | 55% | September 10, 2026 |
| Bollinger Band Breakout | 30 | -3.9% | 47% | May 6, 2026 |
| Bollinger Band Breakdown | 20 | -11.2% | 20% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -9.5% | 20% | July 24, 2026 |
| Any 20-session window (baseline) | -0.5% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RLMD
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready f…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 17
- Website
- www.relmada.com/
Fundamentals
- 1-day range
- $3.73$3.8
- Market cap
- $563.26M
- P/E (trailing)
- —
- P/E (forward)
- -9.23
- EPS (trailing)
- $-0.96
- Dividend yield
- —
- Beta
- 0.56
- Avg. volume
- 1.36M
- Dividend pay date
- September 30, 2019
How Relmada Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2013 annual results
Source: 10-K filed Dec 16, 2013 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Relmada Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone AdvancementSeekingAlpha · 9/14/2026
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 83.57M
- Total value held
- $575.76M
- Institutional holders
- 102
- Unknown11.06M
- Unknown8.47M
- Unknown6.26M
- Unknown4.84M
- Unknown4.76M
- Unknown4.72M
- Unknown4.48M
- Unknown3.91M
- Unknown3.08M
- Unknown2.95M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Relmada Releases Q2 2026 Earnings Call Transcript
Relmada Therapeutics posted the full transcript of its Q2 2026 earnings call. The discussion covered the company’s financial performance for the quarter, updated guidance, and strategic priorities. Investors can review the transcript for details on revenue, expenses, and future outlook. The release provides a comprehensive view of the company’s recent results.
Relmada Releases Q2 2026 Earnings Call Transcript. Relmada Therapeutics posted the full transcript of its Q2 2026 earnings call. The discussion covered the company’s financial performance for the quarter, updated guidance, and strategic priorities. Investors can review the transcript for details on revenue, expenses, and future outlook. The release provides a comprehensive view of the company’s recent results.